Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistance

20 Nov 2014

Abstract excerpt

OBJECTIVES: Strand transfer inhibitors (raltegravir, elvitegravir and dolutegravir) are now commonly used to inhibit HIV-1 integration. To date, three main pathways conferring raltegravir/elvitegravir resistance, involving residues Y143, Q148 and N155, have been described. However, no pathway has been clearly described for dolutegravir resistance. The aim of this study was to characterize the susceptibility of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to HIV/AIDS drug development and treatment
Share to HIV/AIDS Research and Interventions
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25414202
DOI: 10.1093/jac/dku474

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

G118R and F121Y mutations identified in patients failing raltegravir treatment confer dolutegravir resistancePMID 25414202Read ↗

New raltegravir resistance pathways induce broad cross-resistance to all currently used integrase inhibitors.Semantic proximity Read ↗

Differential Effects of the G118R, H51Y, and E138K Resistance Substitutions in Different Subtypes of HIV IntegraseSemantic proximity Read ↗

Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response.Semantic proximity Read ↗

Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance.Semantic proximity Read ↗

Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase.Semantic proximity Read ↗

Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitorsSemantic proximity Read ↗

The G118R plus R263K Combination of Integrase Mutations Associated with Dolutegravir-Based Treatment Failure Reduces HIV-1 Replicative Capacity and Integration.Semantic proximity Read ↗

Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients--impact of HIV subtypes and prior raltegravir experience.Semantic proximity Read ↗

The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.Semantic proximity Read ↗

Progressive emergence of an S153F plus R263K combination of integrase mutations in the proviral DNA of one individual successfully treated with dolutegravir.Semantic proximity Read ↗

The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.Semantic proximity Read ↗

Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.